Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8685443 | ALPHARMA PHARMS | Sequestering subunit and related compositions and methods |
Jul, 2025
(2 years from now) | |
US8685444 | ALPHARMA PHARMS | Sequestering subunit and related compositions and methods |
Jul, 2025
(2 years from now) | |
US8846104 | ALPHARMA PHARMS | Pharmaceutical compositions for the deterrence and/or prevention of abuse |
Jun, 2027
(4 years from now) | |
US8877247 | ALPHARMA PHARMS | Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist |
Jun, 2027
(4 years from now) | |
US7682633 | ALPHARMA PHARMS | Pharmaceutical composition |
Jun, 2027
(4 years from now) | |
US7682634 | ALPHARMA PHARMS | Pharmaceutical compositions |
Jun, 2027
(4 years from now) | |
US8158156 | ALPHARMA PHARMS | Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist |
Jun, 2027
(4 years from now) | |
US7815934 | ALPHARMA PHARMS | Sequestering subunit and related compositions and methods |
Dec, 2027
(4 years from now) | |
US8623418 | ALPHARMA PHARMS | Pharmaceutical composition |
Nov, 2029
(6 years from now) |
Drugs and Companies using MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 13 August, 2009
Treatment: Management of pain severe enough to require daily, around-the-clock, long term opioid treatment by orally administering a plurality of composite subunits as claimed; Management of pain severe enough t...
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
23
United States
9
European Union
7
Australia
5
Spain
5
Denmark
5
Cyprus
5
Portugal
5
Slovenia
4
Poland
4
Hungary
3
Canada
3
Korea, Republic of
2
China
2
Israel
1
Hong Kong
1
Austria
1
Russia
1
Brazil
1
Norway
1
Japan
1
New Zealand
1
Mexico
1
South Africa
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic